EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Adenoviral Gene Therapy Vectors in Clinical Use—Basic Aspects with a Special Reference to Replication-Competent Adenovirus Formation and Its Impact on Clinical Safety

Aleksi J Leikas iD, Seppo Ylä-Herttuala iD, Juha E K Hartikainen iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms242216519 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Aleksi J Leikas und 2 weiteren Autor:innen. Beteiligte Einrichtung: Heart Center, Kuopio University Hospital, 70200 Kuopio, Finland. Hauptthemen laut MEDLINE: Adenoviridae, Genetic Vectors. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 119 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Finnish Foundation for Cardiovascular Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adenoviral vectors are commonly used in clinical gene therapy. Apart from oncolytic adenoviruses, vector replication is highly undesired as it may pose a safety risk for the treated patient. Thus, careful monitoring for the formation of replication-competent adenoviruses (RCA) during vector manufacturing is required. To render adenoviruses replication deficient, their genomic E1 region is deleted. However, it has been known for a long time that during their propagation, some viruses will regain their replication capability by recombination in production cells, most commonly HEK293. Recently developed RCA assays have revealed that many clinical batches contain more RCA than previously assumed and allowed by regulatory authorities. The clinical significance of the higher RCA content has yet to be thoroughly evaluated. In this review, we summarize the biology of adenovirus vectors, their manufacturing methods, and the origins of RCA formed during HEK293-based vector production. Lastly, we share our experience using minimally RCA-positive serotype 5 adenoviral vectors based on observations from our clinical cardiovascular gene therapy studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenoviridaeGenetic VectorsHumansHEK293 CellsGenetic TherapyVirus Replication

Stichwörter der Autor:innen

HEK293VEGF-Dadenovirusgene therapyoncolytic adenovirusesreplication-competent adenovirusesvector shedding

Autor:innen und Institutionen

  • Heart Center, Kuopio University Hospital, 70200 Kuopio, Finland.
  • Gene Therapy Unit, Kuopio University Hospital, 70200 Kuopio, Finland.
  • A. I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, 70210 Kuopio, Finland.
  • School of Medicine, Faculty of Health Sciences, University of Eastern Finland, 70210 Kuopio, Finland.

ORCID-Profile: Aleksi J Leikas, Seppo Ylä-Herttuala, Juha E K Hartikainen

Förderung

  • Wellcome Trust
  • Finnish Foundation for Cardiovascular Research

Zitieren

APA

Leikas, A. J., Ylä-Herttuala, S., & Hartikainen, J. E. K. (2023). Adenoviral Gene Therapy Vectors in Clinical Use—Basic Aspects with a Special Reference to Replication-Competent Adenovirus Formation and Its Impact on Clinical Safety. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms242216519

Vancouver

Leikas AJ, Ylä-Herttuala S, Hartikainen JEK. Adenoviral Gene Therapy Vectors in Clinical Use—Basic Aspects with a Special Reference to Replication-Competent Adenovirus Formation and Its Impact on Clinical Safety. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms242216519

BibTeX
@article{Leikas2023,
  author = {Leikas, Aleksi J and Ylä-Herttuala, Seppo and Hartikainen, Juha E K},
  title = {Adenoviral Gene Therapy Vectors in Clinical Use—Basic Aspects with a Special Reference to Replication-Competent Adenovirus Formation and Its Impact on Clinical Safety},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms242216519}
}
Kostenlos starten →